Blue Arbor closes $10.5M Series A for prosthetic-control studies
Sourced news brief · See the publication date above and original source below.
Michigan-based Blue Arbor Technologies announced the close of a $10.5 million Series A on October 28, led by strategic partner Ottobock.
The company is developing RESTORE, a neuromuscular-interface system intended to help people with upper-limb loss control prosthetic devices. Blue Arbor says the financing will support feasibility work, an FDA Investigational Device Exemption submission for U.S. clinical studies of its external sensing unit, and development of a fully implantable version.
RESTORE has received FDA Breakthrough Device Designation and was accepted into the agency’s TAP pilot, according to the company. Those designations support interaction with the regulator; they are not marketing approval or proof of patient outcomes. Product performance and clinical benefits described in the release remain company claims.
The operating milestones to watch are completion of feasibility testing, authorization to begin the planned U.S. studies, and evidence from those studies. The financing is closed; the clinical and commercial outcomes remain ahead.